Bullish Bayer Highlights Four Future Blockbusters
New Growth Drivers Could Have €12bn Peak Sales
The German group has shone a light at the J.P. Morgan Healthcare Conference on its new launched drugs Nubeqa and Kerendia, plus its late-stage candidates asundexian and elinzanetant, as it prepares for life after patent expiries on Xarelto and Eylea.
You may also be interested in...
The company is struggling to grow revenue, and the biggest of its four key late-stage assets had a setback, but novel technologies are fueling an R&D strategy shift towards high potential programs.
Scrip spoke with Bayer’s head of pharma R&D Christian Rommel at the J.P. Morgan Healthcare Conference about the road ahead for Factor XIa inhibitor asundexian after its atrial fibrillation setback.
The drug maker added three investigator-initiated studies that will enroll more than 9,000 patients to the existing 6,000-patient MOONRAKER program. It has forecast peak sales of